## Rule 6: Align Drugs With Disease Areas

### Rule Definition

Pharmaceutical products should be associated with **clinically appropriate disease areas or diagnoses**. Each drug typically treats one or more specific medical conditions known as **indications**, and datasets should reflect these relationships accurately.

In medical practice and pharmaceutical regulation, drugs are approved for particular diseases or conditions based on clinical evidence. These approved uses are called **drug indications**, and they are defined in official drug labeling and regulatory documentation. ([Wikipedia][1])

Synthetic healthcare datasets must therefore ensure that drug prescriptions or claims correspond logically with the patient’s diagnosis or therapeutic area. If drugs appear with unrelated disease codes, the dataset will produce misleading clinical and market analytics.

---

## Example Mapping

| Product | Typical Diagnosis    |
| ------- | -------------------- |
| Drug A  | Oncology             |
| Drug B  | Diabetes             |
| Drug C  | Rheumatoid Arthritis |

Example claim:

| Patient_ID | Diagnosis   | Product |
| ---------- | ----------- | ------- |
| P030       | Lung Cancer | Drug A  |

Incorrect example:

| Patient_ID | Diagnosis | Product |
| ---------- | --------- | ------- |
| P030       | Diabetes  | Drug A  |

If Drug A is an oncology therapy, pairing it with diabetes diagnoses produces clinically unrealistic data.

---

## Nuances That Must Be Understood

### 1. Drugs Are Approved for Specific Indications

A **drug indication** is the disease or condition for which a medication is approved and intended to treat. Regulatory agencies such as the FDA include these indications in official drug labeling so clinicians know when a drug should be used. ([Wikipedia][1])

Example:

| Drug         | Indication                  |
| ------------ | --------------------------- |
| Metformin    | Type 2 Diabetes             |
| Trastuzumab  | HER2-positive breast cancer |
| Atorvastatin | Hyperlipidemia              |

Synthetic datasets should respect these relationships.

---

### 2. Therapeutic Areas Organize Drug Markets

Pharmaceutical analytics commonly groups drugs by **therapeutic area**.

Typical therapeutic categories:

| Therapeutic Area | Example Conditions  |
| ---------------- | ------------------- |
| Oncology         | Cancer              |
| Endocrinology    | Diabetes            |
| Cardiology       | Hypertension        |
| Neurology        | Epilepsy            |
| Immunology       | Autoimmune diseases |

Analyses such as market share or treatment adoption are performed **within these therapeutic areas**.

If drugs appear in unrelated disease groups, these analyses become meaningless.

---

### 3. Cross-Disease Drug Use Is Rare

Although some medications have **multiple indications**, most uses remain within the same therapeutic system or disease category. Research analyzing drug usage patterns shows that most off-label uses still occur within related therapeutic systems rather than completely unrelated diseases. ([PMC][2])

Examples:

| Drug       | Multiple Indications                         |
| ---------- | -------------------------------------------- |
| Rituximab  | Lymphoma, rheumatoid arthritis               |
| Sildenafil | Erectile dysfunction, pulmonary hypertension |

Even in such cases, the diseases are physiologically related.

Completely unrelated combinations are uncommon.

---

### 4. Diagnosis Codes Should Drive Treatment Selection

In healthcare datasets, treatments are often linked to diagnoses through **diagnosis codes** such as ICD codes.

Example structure:

| Claim_ID | Diagnosis_Code    | Product |
| -------- | ----------------- | ------- |
| C8001    | C34 (Lung Cancer) | Drug A  |

This relationship allows analysts to evaluate:

* Treatment pathways
* Drug utilization by disease
* Treatment effectiveness
* Market penetration within a therapeutic area

If drug-diagnosis relationships are random, these analyses fail.

---

### 5. Drug–Disease Alignment Enables Pharma Analytics

Several pharmaceutical metrics rely on correct drug-diagnosis relationships.

Examples include:

* Market share within a disease category
* New patient starts for a therapy
* Treatment line analysis
* Drug switching patterns
* Comparative effectiveness analysis

Example market share calculation:

| Drug   | Claims |
| ------ | ------ |
| Drug A | 450    |
| Drug B | 320    |
| Drug C | 180    |

If drugs appear in unrelated diseases, these calculations become distorted.

---

## Example Synthetic Mapping Table

A useful approach is to maintain a **Drug–Disease Mapping Table**.

| Product_ID | Therapeutic_Area | Diagnosis_Code |
| ---------- | ---------------- | -------------- |
| DRG001     | Oncology         | C34            |
| DRG002     | Diabetes         | E11            |
| DRG003     | Cardiology       | I10            |

Claims then reference this mapping.

---

## Data Quality Validation Checks

Detect drugs appearing with unrelated diagnoses:

```sql
SELECT c.product_id, c.diagnosis_code
FROM claims c
LEFT JOIN drug_indication_map m
ON c.product_id = m.product_id
AND c.diagnosis_code = m.diagnosis_code
WHERE m.product_id IS NULL;
```

Detect products appearing across unrealistic disease categories:

```sql
SELECT product_id, COUNT(DISTINCT therapeutic_area)
FROM drug_indication_map
GROUP BY product_id
HAVING COUNT(DISTINCT therapeutic_area) > 3;
```

These checks help identify misaligned drug-disease relationships.

---

## Key Takeaway

Pharmaceutical datasets must maintain **logical alignment between drugs and disease areas**. Because medications are developed and approved for specific clinical indications, claims data should reflect those relationships. Proper drug–diagnosis alignment ensures realistic treatment pathways and reliable pharmaceutical analytics.

---

## Points That May Require Verification or Are Context Dependent

Some scenarios require careful modeling:

* Drugs with **multiple approved indications**
* **Off-label prescribing**, where a drug is used outside its approved indication
* Therapies used for **symptom management** rather than the underlying disease

These cases should be modeled deliberately rather than appearing randomly in synthetic datasets.

[1]: https://en.wikipedia.org/wiki/Indication_%28medicine%29?utm_source=chatgpt.com "Indication (medicine)"
[2]: https://pmc.ncbi.nlm.nih.gov/articles/PMC12644437/?utm_source=chatgpt.com "Mapping the therapeutic versatility of WHO essential medicines"
